Supportive care

Daily postdilutional hemodiafiltration with FX800 polysulfone dialyzers for removing kappa light chains inmultiple myeloma-induced kidney injury. Tillmann FP. Indian J Nephrol. 2015 Jul-Aug;25(4):237-41. doi: 10.4103/0971-4065.158176. Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients withMultiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. Satlin MJ et al. Biol Blood Marrow Transplant. 2015 Jul 3. pii: S1083-8791(15)00441-3. doi:…

Details
Journal, Library, Myeloma Prognosis & Outcomes

General

Time to redefine Myeloma. Pratt G et al. Br J Haematol. 2015 Jul 27. doi: 10.1111/bjh.13620. [Epub ahead of print]. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Majithia N et al. Am J Hematol. 2015 Jul 27. doi: 10.1002/ajh.24131. [Epub ahead of print]. Limiting early mortality: Do’s and don’ts in the management of patients with newly diagnosed multiple myeloma. Gonsalves…

Details
Journal, Library

Complications of myeloma and its treatments

Optimizing the management of patients with spinal myeloma disease. Molloy S et al. Br J Haematol. 2015 Jul 17. doi: 10.1111/bjh.13577. [Epub ahead of print]. Measuring therapy-induced peripheral neuropathy: preliminary development and validation of the Treatment-induced Neuropathy Assessment Scale (TNAS). Mendoza TR et al. J Pain. 2015 Jul 22. pii: S1526-5900(15)00763-4. doi: 10.1016/j.jpain.2015.07.002. [Epub ahead of print]. High-dose therapy improves the bone remodelling…

Details
Journal, Library, Management of complications & side effects

Current treatments

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. Ludwig H et al. Br J Haematol. 2015 Jul 7. doi: 10.1111/bjh.13582. [Epub ahead of print]. Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Voorhees PM et al. Br…

Details
Journal, Library

Diagnostic tests and prognostic indicators

Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma. Watanabe T et al. PLoS One. 2015 Jun 26;10(6):e0128662. doi: 10.1371/journal.pone.0128662. High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. Chhabra S et al. J…

Details
Diagnosing and Monitoring Myeloma, Journal, Library

Related conditions

Vasotropic light-chain amyloidosis and ischaemic cholangiopathy. Johnston EL et al. BMJ Case Rep. 2015 Jun 25;2015. pii: bcr2015210883. doi: 10.1136/bcr-2015-210883. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. Cao X et al. J Hematol Oncol. 2015 Jun 24;8(1):74. [Epub ahead of print]. Hepatocyte growth factor measurement in AL amyloidosis. Abraham J et al Amyloid. 2015 Jun 8:1-5. [Epub ahead of…

Details
Journal, Library

Emerging treatments

Safety of a second-generation tyrosine kinase inhibitor and novel targeted therapy for the treatment of a patient with chronic myeloid leukemia and multiple myeloma. Katzel JA et al. Anticancer Drugs. 2015 Jun 23. [Epub ahead of print]. Haematalogical cancer: Elotuzumab reduces risk of multiple myeloma progression. [No authors listed]. Nat Rev Clin Oncol. 2015 Jun 23. doi: 10.1038/nrclinonc.2015.115. [Epub ahead of print]. Lenalidomide…

Details
Journal, Library

Biology and genetics

Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma. Zang M et al. Cancer Lett. 2015 Jun 23. pii: S0304-3835(15)00403-6. doi: 10.1016/j.canlet.2015.06.011. [Epub ahead of print]. Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Kandela I et al. Elife. 2015 Jun 25;4. doi: 10.7554/eLife.07072. KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Riz I et…

Details
Journal, Library, Management of Myeloma